40 results about "Pharmaceutical sciences" patented technology

The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

The present invention relates to the field of antimicrobials and pharmaceutical sciences. The invention provides antifungal compositions for the management of fungal growth and treatment of fungal infections, including treatment of resistant fungal infections. The present compositions comprise at least one antifungal agent and at least one medium-chain saturated or unsaturated fatty acid having carbon chain length of C-1 to C-14 or ester thereof, optionally along with excipient(s), giving rise to a synergistic antifungal activity.

The invention relates to the technical field of medicinal chemistry, in particular to a 2-aminothiazoles compound or acceptable slat in pharmaceutical science, a preparing method thereof, pharmaceutical composition comprising the same, and application thereof in antineoplastic drug preparation.

The invention belongs to the field of medicine processing, and particularly relates to a potassium sodium dehydroandrographolide succinate enteric-coated preparation and a preparation method. The preparation method comprises the specific steps of forming a specific formula based on the effective component potassium sodium dehydroandrographolide succinate and auxiliary materials acceptable in pharmaceutical science, coating an isolation layer and coating an enteric-coated layer through a specific processing technology, then adding suitable auxiliary materials so as to prepare an enteric-coatedcapsule, enteric-coated particles and enteric-coated dry suspension. The refinement method for potassium sodium dehydroandrographolide succinate greatly reduces impurities and lowers occurrence rate of side effects; the special preparation process and parameter for producing the potassium sodium dehydroandrographolide succinate enteric-coated preparation can effectively protect active components of potassium sodium dehydroandrographolide succinate, thereby guaranteeing the medicine effect of the finished product and improving the bioavailability of oral potassium sodium dehydroandrographolidesuccinate. The preparation method has easy steps, is easy to operate and is suitable for industrial production.

The invention provides a novel medical composite for treating diabetic and nephropathy, which comprises insulin sensitizer and endothelin receptor blocker. The invention scientifically combines two medicines with complete different mechanisms of action so as to reach the target of mechanism complementation, mutual coordination, enhancement of treatment effect and rational usage of medicine. The novel medical composite for treating the diabetic and the nephropathy not only has good coordination in reducing blood sugar, but also achieves quite good coordination effect on protecting kidney. The novel medical composite for treating the diabetic and the nephropathy is probably a new breakthrough of the method for treating the diabetic nephropathy.

The invention belongs to the filed of pharmaceutical sciences and particularly relates to ciona intestinalis polypeptide and a preparation method thereof. The ciona intestinalis polypeptide has the N- terminal sequence of YQPDKFMLRGELRNN, the molecular weight of 5931Da and the isoelectric point of 7.25. The preparation method of the ciona intestinalis polypeptide comprises the following steps: precipitating fresh ciona intestinalis by using 10-90% acetone, dialyzing and desalting active components, and purifying by adopting ion-exchange chromatography, gel filtration chromatography and HPLC (high-performance liquid chromatography) to obtain the ciona intestinalis polypeptide which has the molecular weight of 5931Da. The in vivo and in vitro activity experiments verify and confirm that the application of the ciona intestinalis polypeptide to malignant tumor prevention and treatment.

The invention belongs to the field of pharmaceutical science, and particularly relates to a doxycycline hydrochloride dual-release preparation and a preparation method thereof. The preparation consists of micropills with different release performance, namely the preparation is formed by mixing 50 to 85 weight percent of quick-release micropill and 50 to 15 weight percent of sustained-release micropill. The preparation method comprises the following steps of: preparing micropill cores according to a formula, and preparing the quick-release micropills by using the micropill cores; preparing thesustained-release micropills by using the quick-release micropills; and filling the quick-release micropills and the sustained-release micropills into capsules in a ratio to obtain doxycycline hydrochloride dual-release capsules. Pharmacokinetic experiments in the dual-release capsule bodies indicate that medicines in the doxycycline hydrochloride dual-release capsules can be released twice when the doxycycline hydrochloride dual-release capsules are taken once every day, and the concentration of two-time peaks is close; the concentration peak of medicines in blood plasma is reduced by a dual-release model, the possibility of side effect is reduced, and the compliance of the administration of patients is improved; and due to the adoption of a new formula and a new process, the difference among batches is reduced, and the stability of samples is improved, so the doxycycline hydrochloride dual-release preparation is suitable for industrial production.